✦ LIBER ✦

Sequential Combination of Gemtuzumab Ozogamicin and Standard Chemotherapy in Older Patients With Newly Diagnosed Acute Myeloid Leukemia: Results of a Randomized Phase III Trial by the EORTC and GIMEMA Consortium (AML-17)

✍ Scribed by Amadori, S.; Suciu, S.; Stasi, R.; Salih, H. R.; Selleslag, D.; Muus, P.; De Fabritiis, P.; Venditti, A.; Ho, A. D.; Lubbert, M.; Thomas, X.; Latagliata, R.; Halkes, C. J. M.; Falzetti, F.; Magro, D.; Guimaraes, J. E.; Berneman, Z.; Specchia, G.; Karrasch, M.; Fazi, P.; Vignetti, M.; Willemze, R.; de Witte, T.; Marie, J.-P.

Book ID: 126711127
Publisher: American Society of Clinical Oncology
Year: 2013
Tongue: English
Weight: 249 KB
Volume: 31
Category: Article
ISSN: 0732-183X
DOI: 10.1200/JCO.2013.49.0771

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Randomized trial of two schedules of low

Randomized trial of two schedules of low-dose gemtuzumab ozogamicin as induction monotherapy for newly diagnosed acute myeloid leukaemia in older patients not considered candidates for intensive chemotherapy. A phase II study of the EORTC and GIMEMA leukaemia groups (AML-19)

✍ Sergio Amadori; Stefan Suciu; Dominik Selleslag; Roberto Stasi; Giuliana Alimena 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 119 KB

Clofarabine in combination with a standa

Clofarabine in combination with a standard remission induction regimen (cytosine arabinoside and idarubicin) in patients with previously untreated intermediate and bad-risk acute myelogenous leukemia (AML) or high-risk myelodysplastic syndrome (HR-MDS): phase I results of an ongoing phase I/II study of the leukemia groups of EORTC and GIMEMA (EORTC GIMEMA 06061/AML-14A trial)

✍ Willemze, R.; Suciu, S.; Muus, P.; Halkes, C. J. M.; Meloni, G.; Meert, L.; Karr 📂 Article 📅 2014 🏛 Springer 🌐 English ⚖ 197 KB